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RUNNING TITLE 
The chromatin landscape of atypical teratoid rhabdoid tumors 
 
 
SUMMARY  
 
Biallelic inactivation of SMARCB1, encoding a member of the SWI/SNF chromatin remodeling 
complex, is the hallmark genetic aberration of atypical teratoid rhabdoid tumors (ATRT). Here, we 
report how loss of SMARCB1 affects the epigenome in these tumors. Using ChIP-sequencing on 
primary tumors for a series of active and repressive histone marks, we identified the chromatin 
states differentially represented in ATRTs compared to other brain tumors and non-neoplastic brain. 
Re-expression of SMARCB1 in ATRT cell lines enabled confirmation of our genome-wide findings for 
the chromatin states. Additional generation of ChIP-seq data for SWI/SNF and Polycomb group 
proteins and the transcriptional repressor protein REST determined differential dependencies of 
SWI/SNF and Polycomb complexes in regulation of diverse gene sets in ATRTs.  
 
SIGNIFICANCE  
Global loss of H3K27ac-associated chromatin states in ATRTs, compared to non-neoplastic tissue and 
other brain tumors, is not compensated by a global increase of repressive marks. Instead, H3K27me3 
enrichment, strongly correlated with binding of EZH2 and REST, is mostly restricted to SMARCB1 
binding sites, resulting in repression of neuronal differentiation genes. A substantial fraction of 
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SMARCB1 binding sites in ATRTs is bound by EZH2 but lacks H3K27me3. Residual SWI/SNF complex 
binding, measured by SMARCA4 ChIP-seq, maintains these genes in an active state, even in the 
presence of Polycomb complex and REST. This divergent interplay between SWI/SNF and Polycomb 
hints at novel potential vulnerabilities in this dreadful disease, but also provides insights into fine-
tuned regulatory networks relevant beyond ATRT biology. 
 
HIGHLIGHTS  
 ATRT epigenomes display a global depletion of H3K27ac and H3K27me3 
 Neuronal genes bound by SMARCB1 in normal brain are repressed by EZH2 in ATRT 
 ATRT harbor many active genes occupied by EZH2 but without occupancy of H3K27me3 
 Residual SWI/SNF occupancy maintains genes active in the presence of Polycomb  
 
INTRODUCTION 
SWI/SNF complexes are chromatin remodelers consisting of multiple subunits, which mobilize 
nucleosomes (Kadoch et al., 2016). Approximately twenty percent of all human cancers have been 
shown to have mutations in one of the subunits of SWI/SNF complex (Kadoch et al., 2013). One of 
the subunits of SWI/SNF complex, SMARCB1 (also known as SNF5, BAF47, or INI1), is biallelically 
inactivated in roughly 95% of all malignant rhabdoid tumors (MRT). This is a group of highly 
aggressive tumors, which is seen in infants and young children mainly in kidney (rhabdoid tumor of 
the kidney - RTK), brain (atypical teratoid rhabdoid tumor - ATRT) and to a smaller extent in soft 
tissue and liver (Masliah-Planchon et al., 2015). In about 5% of MRT cases an inactivating mutation of 
SMARCA4 and not SMARCB1 is found, resulting presumably in the same consequence, which is the 
inactivation of the SWI/SNF complex (Hasselblatt et al., 2014; Schneppenheim et al., 2010). Recent 
studies characterizing the genomic landscape of ATRTs and extra-cranial MRTs reported stable 
genomes and inactivation of SMARCB1 largely by structural aberrations in the analyzed cases (Chun 
et al., 2016; Johann et al., 2016; Torchia et al., 2016).  
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Atypical teratoid rhabdoid tumors are highly malignant tumors of the central nervous system mainly 
seen in children younger than three years old and recognized as the most frequent malignant brain 
tumor in children younger than six months (Biswas et al., 2016). ATRT patients have a very poor 
prognosis with a median survival of around 17 months and existing therapy options mainly consist of 
chemotherapy and radiation. Although new therapeutic approaches – such as interference with EZH2 
activity – are being developed, specificity and safety of these new therapy options need to be further 
studied (Ginn and Gajjar, 2012). Recent genomic studies characterizing ATRTs (Johann et al., 2016; 
Torchia et al., 2016) provided fundamental insights into molecular characteristics of this deadly 
disease. Importantly, we previously showed that ATRT consists of three molecular subgroups, termed 
ATRT-TYR, ATRT-SHH and ATRT-MYC, each characterized by distinct pathways aberrantly regulated 
(Johann et al., 2016). However, a comprehensive epigenetic characterization of the ATRT epigenome 
with respect to the loss of SMARCB1 has not been attempted in any of these recent landmark 
studies. 
 
Over the last few years studies performed by ENCODE, Roadmap and IHEC projects investigated the 
epigenomic landscape of diverse non-pathogenic tissue/cell types and a few cancer cell lines by 
profiling histone modifications with active and repressive characteristics and integrating with 
transcriptomic and methylome data sets (Encode Project  Consortium, 2012; Roadmap Epigenomics 
Consortium et al., 2015; Stunnenberg et al., 2016). The results of these studies gave important hints 
about chromatin organization in mostly physiological cell types. Given the high rate of dysregulation 
of chromatin modifiers in cancer (Brien et al., 2016) and the large discrepancy between cancer cell 
lines and primary cancers (Lin et al., 2016), studies characterizing chromatin landscapes of primary 
tumors are needed for complete molecular characterization of diverse tumors. Within the context of 
rhabdoid tumors, recent studies have shed more light on the function of SMARCB1 binding at 
enhancer elements (Johann et al., 2016; Torchia et al., 2016; Wang et al., 2017), but other global and 
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focal effects of SMARCB1 loss on the epigenome remain understudied. Despite being known as the 
genetic hallmark in rhabdoid tumors for more than two decades, there is still much unknown how 
loss of SMARCB1 drives ATRT tumorigenesis. A better understanding of the molecular mechanisms 
behind this is urgently needed in order to develop novel treatment strategies for patients with 
rhabdoid tumors who still face a very poor outcome (Fruhwald et al., 2016). Therefore, to assess the 
effect of SMARCB1 loss on the global distribution of histone modifications and chromatin states, we 
performed chromatin immunoprecipitation for six different types of histone modifications followed 
by sequencing (ChIP-seq) in 11 primary ATRT representing all three recently identified molecular 
subgroups (5 ATRT-TYR, 3 ATRT-SHH, 3 ATRT-MYC) (Johann et al., 2016) (Table S1) and identified 
chromatin states specifically represented in ATRTs. Further, integration of histone modification data 
with chromatin modifier localizations enabled the discovery that residual SWI/SNF activity is present 
in ATRT at genes important for tumorigenesis where it keeps these genes active despite the presence 
of the repressor EZH2. 
    
RESULTS 
The chromatin landscape of ATRT  
Histone modifications associated with active chromatin organization and gene transcription 
(H3K27ac, H3K4me1, H3K4me3, H3K36me3) as well as gene repression (H3K27me3, H3K9me3) were 
analyzed, together representing the six core histone marks as analyzed by the IHEC, Roadmap, and 
ENCODE consortia (Encode Project  Consortium, 2012; Roadmap Epigenomics Consortium et al., 
2015; Stunnenberg et al., 2016). ATRT data were compared to corresponding sets of ChIP-Seq data 
generated for medulloblastoma (MB; n = 23), pediatric glioblastoma (pGBM; n = 3), pediatric normal 
brain (PNB; n = 1), and published data (Roadmap Epigenomics Consortium et al., 2015) for adult 
normal brain (ANB; n = 7) and embryonic stem cells (ESC; n = 5). To segment individual genomes into 
functionally distinct chromatin states, we applied the Roadmap 18-state chromatin segmentation 
model using chromHMM (Ernst and Kellis, 2012) (Figure 1A).  
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Quantification of the relative genomic fractions assigned to the 18 different chromatin states in 
ATRTs and other tissues showed that active enhancer states defined by co-occupancy of H3K27ac 
and H3K4me1 (e.g. EnhA1) and actively transcribed states defined by H3K36me3 (e.g. Tx), were 
significantly (p < 0.05) underrepresented in ATRTs as compared to other pediatric brain tumors and 
PNB (Figure 1B-1C). The active promoter state (TssA, defined by H3K4me3 and H3K27ac) was also 
globally depleted in ATRTs compared to PNB and ANB, but was similarly represented in other brain 
tumors (Figure 1D). The relative fraction of the active flanking transcription start site downstream 
(TssFlnkD) state defined by H3K4me1 and H3K4me3 but lacking H3K27ac, was however significantly 
increased in ATRTs when compared with most other tissues (Figure 1E). These observations imply a 
selective loss of only H3K27ac-associated active states rather than a reduction of all active chromatin 
states in ATRT. 
   
Surprisingly, however, the global loss of H3K27ac-associated active states in ATRTs was not 
compensated by a global increase in repressive states. Instead, repressed polycomb states (e.g 
ReprPC) defined exclusively by H3K27me3, were largely depleted from ATRT genomes, especially 
when compared to PNB and other brain tumors (Figure 1F). Furthermore, we observed an 
overrepresentation of the quiescent state in ATRTs, which is devoid of any of the six histone marks 
covering ~70% of the genome (Figure 1G). In line with the embryonal origin of ATRTs (Pfister et al., 
2010), the relative fractions of most chromatin states were overall rather similar to ESC (Figure S1A). 
Analyzing chromatin states for each of the three molecular subgroups of ATRTs separately revealed 
clear differences in the chromatin states of previously described subgroup-specific signature genes 
(Johann et al., 2016), for instance CCND1, FOXK1 or HOXC (Figure 1H). We did not, however, observe 
major differences in genome-wide relative fractions of the different chromatin states between ATRT 
subgroups compared with other tissue types (Figure S1A), suggesting that SMARCB1 loss results in a 
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global depletion of H3K27ac and H3K27me3 marks, which was confirmed by quantitative 
comparisons and mass spectrometry analyses as well (Figure S1B-S1F).  
 
Because of the unexpected global depletion of the H3K27me3-associated ReprPC state in ATRT we 
were interested in understanding to which chromatin states such genetic regions have switched. 
Most frequently, regions annotated as ReprPC states in PNB switched in ATRT to a quiescent state or 
to a weakly repressed Polycomb state (ReprPCWk) characterized by low H3K27me3 abundance 
(Figure S2A-S2B). When integrating DNA methylation data, genomic regions annotated as ReprPC in 
PNB and switching to different states in ATRT show significantly higher DNA methylation levels in 
ATRT compared with regions that remain in ReprPC state in ATRTs (Figure S2C), suggesting 
replacement of Polycomb-mediated repression of genomic regions in PNB by DNA methylation in 
ATRT.  
 
Re-expression of SMARCB1 in ATRT cell lines results in global gain of H3K27ac  
To validate the epigenetic changes observed in primary tumors caused by SMARCB1 loss, we re-
expressed SMARCB1 in two ATRT cell lines, BT12 and BT16, via transducing the cells with lentivirus 
expressing SMARCB1 (Figure 2A). Immunoblotting confirmed expression of SMARCB1 protein in both 
BT12 and BT16 at physiological levels (Figure S3A). In line with previous observations (Ae et al., 2002; 
Betz et al, 2002), we saw a substantial reduction of the cell density after re-expression of SMARCB1 
for both cell lines as measured by bioluminescence (Figure S3B), caused by an early G1 cell cycle 
arrest and cellular senescence, followed by apoptosis (Figure S3C-S3F).  
 
Next, we performed H3K27me3 and H3K27ac ChIP-seq on BT12 and BT16 cell lines before and after 
SMARCB1 re-expression. In both cell lines, SMARCB1 re-expression resulted in a substantial increase 
of regions with higher H3K27ac occupancy compared with the parental cell line lacking SMARCB1 
(Figure 2B-2C). In BT16 cells, we also found an increase in H3K27me3, which was, however, less 
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pronounced in BT12 cells (Figure S3G-S3H). Mass spectrometry analyses measuring H3K27ac and 
H3K27me3 levels before and after SMARCB1 re-expression confirmed these increased levels of 
H3K27ac and H3K27me3 (Figure S3I). The great majority of regions gaining H3K27ac were promoter-
distal as compared to regions losing H3K27ac (Figure 2D-2E), consistent with recent studies showing 
enrichment of the SWI/SNF complex at TSS-distal regions after SMARCB1 re-expression (Wang et al., 
2017). Notably, 80% of the genomic regions gaining H3K27ac in BT12 overlapped the genomic 
regions gaining H3K27ac in BT16 (Figure 2F-2G), suggesting for a mechanistic baseline guiding de 
novo deposition of H3K27ac after re-expression of SMARCB1. Further, regions that gained H3K27ac in 
both cell lines were significantly enriched for H3K27ac-defined chromatin states in PNB as compared 
to ATRT (Fisher’s exact test p value < 2.2e-16 and odds ratio=3.7). These results argue that SMARCB1 
re-expression induces a remodeling of chromatin states towards the distribution observed in normal 
pediatric brain tissue.  
 
We performed RNA-seq to identify differentially expressed genes after SMARCB1 re-expression in 
BT12 and BT16 cell lines. Downregulated genes were mainly involved in stress response and 
metabolism while upregulated genes included many genes involved in neuron development such as 
UNC5C, NDRG1 and NEDD4L (Figure S3J). Furthermore, we observed a positive correlation (ρ=0.59) 
between changes in gene expression and changes in H3K27ac levels at genes upregulated after 
SMARCB1 re-expression (Figure 2H). Overall, these data re-emphasize the anti-proliferative functions 
of SMARCB1 but more importantly validate the findings of a global H3K27ac and H3K27me3 
reduction in primary tissue. 
 
Chromatin landscape at SMARCB1 binding sites in ATRT  
Although several studies investigated the pathways deregulated upon SMARCB1 depletion in in vitro 
models (Johann et al., 2016; Kim and Roberts, 2014; Torchia et al., 2016; Wang et al., 2017; Wilson et 
al., 2010), the changes that occur in chromatin organization at SMARCB1 bound-genomic regions 
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after SMARCB1 loss are unknown. Therefore, beyond the global effects of SMARCB1 loss on the ATRT 
epigenome (Figure 1), we were specifically interested in epigenetic alterations at genomic regions in 
ATRTs that are bound by SMARCB1 in non-neoplastic tissue. Thus, we generated SMARCB1 ChIP-seq 
data in PNB and compared the representation of chromatin states in PNB and ATRTs at SMARCB1 
binding sites. Similar to what has been observed on a genome-wide level, our analysis revealed a 
reduced representation of active chromatin states, especially of active enhancer states, and 
increased representation of quiescent chromatin states in ATRT compared to PNB at SMARCB1 
binding sites (Figure 3A). However, in contrast to the genome-wide findings, Polycomb-mediated 
repressed chromatin states were enriched in ATRT in regions bound by SMARCB1 in PNB (Figure 3A), 
without major differences between ATRT subgroups (Figure S4A). These results demonstrate for the 
first time at a genome-wide scale the transition from active to repressed chromatin organization at 
SMARCB1 binding sites in primary tumors. 
 
A more detailed analysis of promoters bound by SMARCB1 in PNB and characterized by a repressed 
chromatin state in ATRTs showed that regions surrounding the TSS indeed were specifically depleted 
for H3K27ac and gained H3K27me3 (Figure 3B). This is in line with the classical hypothesis that 
SMARCB1 depletion results in gain of H3K27me3 at specific gene loci. Expression levels of these 
genes were significantly lower in ATRT compared to PNB (Figure S4B). Pathway analysis revealed a 
significant enrichment of transcription factors involved in neuronal differentiation such as NEUROD2, 
EN2 and LHX1, and known tumor suppressor genes (TSGs) (Zhao et al., 2013) such as WNK2 (Figure 
3C, Figure S4C-S4D) that appear to be repressed through this mechanism in ATRT. These results are 
fully in agreement with previous studies showing defects in neuronal differentiation in the absence 
of SMARCB1 in murine cell lines (Albanese et al., 2006) and repression of lineage specific genes in 
SMARCB1-deficient cell lines (Wilson et al., 2010) and further serve as a reference guide of 
SMARCB1-targeted yet repressed genes in a primary tumor deficient for SMARCB1 (Table S2).   
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SMARCB1-occupied genes are mainly silenced by EZH2  
The histone methyltransferase EZH2, part of the Polycomb repressive complex 2 (PRC2), is 
responsible for establishing most H3K27me3 marks in the genome and has been described as an 
important epigenetic modifier in ATRT (Alimova et al., 2013; Kadoch et al., 2016; Moreno and Kerl, 
2016). Despite the known interplay between Polycomb and SWI/SNF complexes (Kadoch et al., 
2016), genetic targets of EZH2 in the context of SMARCB1-deficiency are very limited and restricted 
to rhabdoid cell lines (Wilson et al., 2010). To better understand the role of EZH2 in chromatin 
organization of ATRT, we generated genome-wide EZH2 ChIP-seq data for ATRTs across all three 
subgroups (Table S1). Identification of EZH2-occupied promoters revealed that eighty percent of all 
promoters bound by SMARCB1 in PNB and repressed in ATRT were indeed targeted by EZH2 (Figure 
4A-4B). These data support the role of EZH2 in (a) establishing the transition from active to repressed 
chromatin states via deposition of H3K27me3 at SMARCB1 binding sites in ATRT and (b) being a 
rational therapeutic target. The other 20% of SMARCB1 bound promoters had no EZH2 binding in 
ATRT (Figure 4A), suggesting repressed chromatin organization at these loci without EZH2 
involvement. Transcription factor motif enrichment analysis using known motifs (Figure 4C) and de 
novo identified motifs (data not shown) at SMARCB1-bound sites in promoters with repressive 
chromatin organization in ATRT pointed to the potential involvement of REST, a neuronal 
transcriptional repressor involved in chromatin organization (Arnold et al., 2013; Meier and Brehm, 
2014). Interestingly, expression of REST was significantly higher in ATRT compared to PNB (Figure 
4D). We performed REST ChIP-seq in seven primary ATRTs and identified REST to co-localize with  
EZH2 at SMARCB1 bound yet repressed genes in ATRT (Figure 4E). Plotting the REST occupancy 
surrounding ± 5kb TSS of such genes revealed REST localization often extending into gene body  
(Figure 4F), in line with EZH2 localization pattern at those loci (Figure 4G). Overall, these data suggest 
that in the absence of SMARCB1, EZH2 binding leads to gene silencing, probably in concert with other 
transcriptional repressors such as REST. 
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Genes marked by EZH2 without H3K27me3 in ATRTs are expressed and are associated with active 
chromatin states  
Given the fact that we identified a large group of promoters which were SMARCB1 bound in PNB to 
be targeted by EZH2 in ATRT (Figure 4A), we thoroughly characterized EZH2 and H3K27me3 dynamics 
at all promoters in ATRT (Figure 5A). Surprisingly, we identified a large group of promoters bound by 
EZH2 but devoid of H3K27me3 (EZH2+/H3K27me3- promoters representing ~38% of all promoters, 
see also Figure S5A-S5B for the derivation of the applied cut-offs). EZH2+/H3K27me3- promoters were 
much more abundant than promoters with the expected co-occurrence of EZH2 and H3K27me3 
(EZH2+/H3K27me3+, ~11% of all promoters). EZH2+/H3K27me3- promoters were present in all three 
ATRT subgroups (Figure S5C-S5E) and also very clearly present in BT16 ATRT cell line (Figure S5F) (no 
data for BT12) and in PNB (Figure S5G), but largely absent in ESC (Ku et al., 2008) (Figure S5H). ChIP-
qPCR experiments confirmed the existence of a class of genes in ATRT that were occupied by EZH2 
but had no H3K27me3 (Figure S5I-S5K). Existence of genes marked by EZH2 without H3K27me3 was 
previously shown for castration resistant prostate cancer cells (Xu et al., 2012). Here, we show that 
this is a prevalent class of genes in primary ATRTs and normal pediatric brain tissue as well.  
 
Genes with EZH2+/H3K27me3- promoter status in ATRT were expressed at significantly higher levels 
(Figure 5B), showed promoter-hypomethylation (Figure 5C), and were associated with active 
chromatin states (Figure 5D), compared to genes associated with EZH2+/H3K27me3+ promoters. The 
genes with promoters in EZH2+/H3K27me3- status and associated with EZH2 enrichments in the 
upper 5th percentile were significantly enriched for pathways regulating translation, cell cycle and 
chromatin organization (Table S3).  
 
Residual SWI/SNF activity maintains EZH2-occupied genes active  
It has been reported that loss of SMARCB1 causes disassembly of most SWI/SNF complexes at 
promoters and typical enhancers, but it is also known that there must be residual SWI/SNF activity in 
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the absence of SMARCB1 as rhabdoid cell lines have been shown to depend on SMARCA4 (Alver et 
al., 2017; Wang et al., 2017). To test whether residual SWI/SNF complex occupancy may be 
responsible for the active chromatin organization at EZH2+/H3K27me3- promoters, we generated 
SMARCA4 ChIP-seq data in different ATRTs across all three subgroups. Indeed, nearly all 
EZH2+/H3K27me3- promoters revealed SMARCA4 binding (Figure 6A, Figure S6) and 92.5% of them 
overlapped with SMARCB1 binding sites in PNB as well (Figure S7A). In contrast, EZH2+/H3K27me3+ 
promoters showed almost no SMARCA4 binding (Figure 6B, Figure S6) and only 17.0% of such 
promoters showed both SMARCA4 occupancy in ATRT and SMARCB1 occupancy in PNB (Figure S7B). 
Additional ChIP-seq data generated for SUZ12, another component of the PRC2 complex 
(Grossniklaus and Paro, 2014), showed co-localization of SUZ12 with EZH2 at both EZH2+/H3K27me3- 
and EZH2+/H3K27me3+ promoters (Figure 6A-6B, Figure S6). Interestingly, we also identified REST to 
anchor at TSS of EZH2+/H3K27me3- genes. However, as opposed to the localization at SMARCB1 
bound yet repressed genes (~80% EZH2+/H3K27me3-  status), REST binding at active loci was only 
focused at TSS without extension into the gene body (Figure S7C), consistent with previous 
publications (Rockowitz et al., 2014). Interestingly, in contrast to SMARCB1 bound yet repressed 
genes, we found no enrichment of the REST binding motif at these active loci, suggesting that REST is 
here not binding directly to the DNA. Altogether, these data suggests that residual SWI/SNF binding, 
as measured by SMARCA4 binding, ensures gene activity, and also enables oncogene activation such 
as CDK4, a prominent cell cycle gene deregulated in rhabdoid tumors (Moreno and Kerl, 2016), even 
in the presence of Polycomb complex (Figure 6C). Our findings, which demonstrate co-localization of 
SUZ12 together with EZH2 at EZH2+/H3K27me3- promoters (Figure 6A), make it unlikely that EZH2 
specifically has a direct role on activation of EZH2+/H3K27me3- genes though an activating role for 
the whole PRC2 can not be directly excluded. To investigate this, we silenced EZH2 expression in 
BT16 cells using an inducible shRNA (Figure S7D) and analyzed gene expression profiles by RNA-seq. 
Differential gene expression analyses showed that 1151 genes were significantly ≥2-fold upregulated 
after EZH2 knock-down, including 712 genes annotated as EZH2+/H3K27me3- genes and 110 genes 
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annotated as EZH2+/H3K27me3+ genes (Figure S7E). ATRT ChIP-seq data for H3K27me3 showed that 
upregulated genes after EZH2 knock-down in BT16 cells display significantly higher H3K27me3 levels 
in primary ATRTs than downregulated genes, not only for  EZH2+/H3K27me3+ genes, but also for 
EZH2+/H3K27me3- genes where in general the H3K27me3 levels are much lower (Figure S7F, note 
that scales are different between left and right panel). These data suggest that upregulated genes 
after EZH2 knock-down are suppressed by EZH2 in ATRTs, not only for EZH2+/H3K27me3+ genes, but 
also for EZH2+/H3K27me3- genes. However, suppression by EZH2 for the EZH2+/H3K27me3- genes is 
less strong, as reflected by the overall much lower levels of H3K27me3, due to the residual SWI/SNF 
complex present at these sites. Altogether, these data suggest that EZH2 still most likely acts as 
suppressor and not as an activator at EZH2+/H3K27me3- genes.  
 
The existence of residual SWI/SNF activity in the absence of SMARCB1 has previously been 
implicated by showing that rhabdoid cell lines depend on SMARCA4 (Wang et al., 2009). While we 
found a significant reduction in representation of active enhancer state in ATRT (Figure 1B), we were 
interested in evaluating whether the residual SWI/SNF complex was present at enhancers that 
remained active in ATRT. We identified SMARCA4 localization at ATRT subgroup specific enhancers 
and the pattern of SMARCA4 occupancy in ATRT subgroups was concordant with the subgroup-
specificity of the enhancers (Figure 6D). SMARCA4 binding at enhancers contained or not-contained 
within super-enhancers were largely comparable (Figure S7G). Further, co-localization of SMARCA4 
and EZH2 was also found at active enhancers and super-enhancers, previously identified by genome-
wide H3K27ac profiling (Johann et al., 2016) (Figure S7H-S7J).  
 
As EZH2+/H3K27me3- class of promoters were also present in PNB (Figure S5G), we wondered about 
SWI/SNF and Polycomb interplay at such promoters in PNB. Interestingly, we identified a strong 
correlation between EZH2 and SMARCB1 occupancy and EZH2 and SMARCB1 co-localization at 
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EZH2+/H3K27me3- promoters in PNB (Figure S7K-S7L), indicating that the SWI/SNF and Polycomb co-
localization does not specifically occur in ATRTs but also in normal tissue.  
 
SMARCA4 knock-down in ATRT cell lines results in growth arrest and reduction in the expression of 
genes occupied by EZH2 without H3K27me3.  
The binding of SMARCA4 at EZH2+/H3K27me3- promoters suggests that this SWI/SNF member may 
impede EZH2 function at these genes and thus maintains these genes in an active state. To validate 
this hypothesis, we performed SMARCA4 knock-downs in BT12 and BT16 ATRT cell lines using 
shRNAs (Figure S7M). SMARCA4 knock-down led to substantial reduction in growth rate in both ATRT 
cell lines caused by an increase in apoptosis (Figure 7A-7B). In comparison, SMARCA4 knock-down 
did not result in robust changes in growth rate of 293T cells, which has intact SMARCB1 (Figure 7A). 
SMARCA4 knockdown led to a downregulation of several key genes (Figure 7C), such as CCND3 and 
CDK6 related to cell death and survival and cell growth and proliferation, suggesting that SMARCA4 
has an essential role in maintaining the proliferation and viability of rhabdoid cells. Furthermore, 
these genes have EZH2+/H3K27me3- promoter states in BT16 cell line, implying that reduction in the 
activity of SMARCA4 will result in an increase of H3K27me3 and loss of activity of the genes with 
EZH2+/H3K27me3- promoter status. Indeed, quantification of H3K27me3 levels by ChIP-qPCR after 
SMARCA4 knockdown showed a significant increase of H3K27me3 at these genes (Figure 7D). 
 
DISCUSSION  
In this study, we present a full characterization of chromatin state dynamics in a primary tumor 
deficient for SMARCB1 by generating ChIP-seq data for six histone marks for 11 ATRTs representing 
all three molecular subgroups. Our data demonstrate a global loss of H3K27ac and H3K27me3 in the 
absence of SMARCB1 in ATRT (Figure 1). We identify genome-wide loss of H3K27ac-associated 
chromatin states in ATRT rather than a non-specific loss of all other active histone mark-associated 
states. Importantly, even though EZH2 expression is strongly upregulated in ATRT (Alimova et al., 
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2013), this does not result in a global increase in H3K27me3 levels. In contrast, we observed a 
globally decreased H3K27me3 signal, in line with immunohistochemical observations (Hasselblatt et 
al., 2017; Kakkar et al., 2016; Venneti et al., 2014). As suggested previously, EZH2 overexpression 
might mainly be explained by the need to maintain H3K27me3 levels in proliferating cells (Wassef et 
al., 2015).  
 
The epigenetic changes caused by SMARCB1 loss in ATRT were further validated in SMARCB1 re-
expressing ATRT cell lines (n=2) by both ChIP-seq and gene expression profiling; in particular our 
findings re-emphasize the anti-proliferative functions of SMARCB1.  
 
Although previous studies have highlighted the importance of EZH2 in rhabdoid tumors (Alimova et 
al., 2013; Kakkar et al., 2016; Kheradmand Kia et al., 2009; Knutson et al., 2013; Kurmasheva et al., 
2017; Morel et al., 2017; Moreno and Kerl, 2016), its main targets in primary tumors so far remained 
ill-defined. Here, we re-define EZH2/Polycomb complex dynamics in ATRT. Our data show that 
residual SWI/SNF complex and Polycomb complex are co-localized at active genes in ATRTs where 
the residual SWI/SNF protects against Polycomb-mediated repression. At repressed genes - such as 
neuronal differentiation genes - the binding of residual SWI/SNF complex is most likely impeded by 
REST. These genes display an enrichment for REST signal, which probably directs the PRC2 complex to 
these genes, setting H3K27me3 marks. On the other hand, at enhancers and the majority of 
promoters, residual SWI/SNF localization ensures subgroup/lineage-specific enhancer activity, gene 
activity and possibly oncogene activation even in the presence of Polycomb (Figure 8). At these 
genetic regions we also did not detect any REST binding motif, and although REST signal is not 
completely absent in these regions, signals are much narrower than at repressed genes. This is also in 
accordance with previous data, showing narrow signals of REST at active genes (Rockowitz et al., 
2014).  
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Hypothesizing that both the lineage determination as well as the oncogenic drive is dependent on 
residual SWI/SNF - EZH2 function in ATRT, design of therapies targeting residual SWI/SNF complex 
components alone or in combination with EZH2 inhibition might be beneficial for treatment of ATRT 
patients. However, therapies based on EZH2 inhibition alone may have the risk that not only 
repressed genes are re-activated but that active genes also become more active. As the 
malfunction/mutation of both SWI/SNF and Polycomb complexes is prevalent in many cancer types 
(Brien et al., 2016), and given the fact that we identified co-localization of SWI/SNF and Polycomb 
complexes at active genes both in ATRT and non-neoplastic tissue despite their known antagonistic 
functions (Kadoch et al., 2016), our findings will give directions both to the understanding of the 
basic biology between these complexes and discovery of novel regulatory mechanisms appearing as 
a result of their disruption. 
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FIGURE LEGENDS 
 
Figure 1. The chromatin segmentation landscape of ATRT.  
(A) Roadmap 18-state chromatin segmentation model and the analyzed histone modifications. 
(B-G) Comparison of the representation of selected chromatin states in ATRT (n=11) to the ones in 
GBM (n=3), MB (n=23), adult normal brain (Roadmap Epigenomics Consortium et al., 2015) (ANB) 
(n=7), pediatric normal brain (PNB) (n=1), and ESC (Roadmap Epigenomics Consortium et al., 2015) 
(n=5). Boxplots show the coverage of the selected chromatin states in the genome that show 
significant variability in ATRTs when compared to other tissues (EnhA1 (B), Tx (C), TssA (D), TssFlnkD 
(E), ReprPC (F), and Quies (G)) in the genome. *Pair-wise t-test, adjusted p value < 0.05.  
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(H) Snapshots show the overlayed histone modification profiles and chromatin segmentation 
produced using the Roadmap 18-state model for selected ATRT signature genes for 11 ATRTs 
representing ATRT-TYR (n=5), ATRT-SHH (n=3) and ATRT-MYC (n=3) subgroups at CCND1 locus, 
FOXK1 locus and HOXC cluster.  
See also Figure S1 and S2  and Table S1. 
 
Figure 2. Re-expression of SMARCB1 in BT16 and BT12 ATRT cell lines results  in global gain of 
H3K27ac.  
(A) Cartoon illustrating the experiments carried out in BT12 and BT16 ATRT cell lines after re-
expression of SMARCB1.  
(B-C) MA (M, log-ratio, A, mean average) plot-comparisons of average H3K27ac levels and log2 fold 
changes after SMARCB1 re-expression indicate a substantially higher number of 2kb windows tiling 
the genome that gained H3K27ac compared to the ones that lose H3K27ac. Experiments were done 
for BT12 (B) and BT16 (C). Red dashed lines indicate the log2 fold changes at 0.5 and -0.5.  
(D-E) Pie-charts display the genomic representation of the regions gaining or losing H3K27ac after 
SMARCB1 re-expression in BT12 (D) and BT16 (E).  
(F) Venn-diagram showing the overlap of the genomic regions gaining H3K27ac after SMARCB1 re-
expression in BT12 and BT16 cell lines.  
(G) Snapshot displays H3K27ac (orange) and H3K27me3 (gray) signal at the genomic region 
chr22:30,578,739-30,634,209 before and after SMARCB1 re-expression in BT12 cell line (top panel) 
and BT16 cell line (bottom panel).  
 (H) Scatter plot shows the correlation between average log2 fold change in expression and average 
log2 fold change in H3K27ac after re-expression of SMARCB1 in BT12 and BT16 cell lines. 
See also Figure S3. 
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Figure 3. SMARCB1 binding sites: Repression of SMARCB1-bound genes via gain of H3K27me3 in 
ATRT.  
(A) Representation of SMARCB1 binding sites at different chromatin states in ATRT and pediatric 
normal brain (indicated as “normal” on the plot) highlights the association of SMARCB1 binding sites 
preferentially with repressed chromatin states in ATRT. Observed/expected state frequencies at 
SMARCB1 binding sites refer to the calculated odd ratios upon comparing the chromatin state 
representations at SMARCB1 binding sites with the genomic regions with similar genomic 
characteristics as SMARCB1 binding sites. See methods for details. H3K27ac-dominated and 
H3K27me3-dominated chromatin states are indicated with red and gray stars, respectively.  
(B) Heatmaps displaying scaled-read densities for H3K27ac and H3K27me3 surrounding ± 2 kb TSS of 
the genes which are SMARCB1 bound in pediatric normal brain (normal) and comprise repressed 
chromatin states in ATRT (n=1791 unique promoters corresponding to n=689 unique genes).  
(C) Association of SMARCB1 bound yet repressed promoters with neuronal differentiation genes in 
ATRT. Left panel shows the pathway enrichment analysis for the same set of genes as in (B). 
Snapshot (right panel) displays the SMARCB1 signal and the active chromatin states in pediatric 
normal brain (n=1), and repressed chromatin states in ATRT subgroups (TYR, n=5, SHH, n=3, MYC, 
n=3) at NEUROD2 locus. The expression level of NEUROD2 in ATRT subgroups in comparison to 
pediatric normal brain is presented as boxplot right to the image.  
See also Figure S4 and Table S2. 
 
Figure 4. SMARCB1 bound genes in pediatric normal brain are mainly repressed via EZH2 in ATRT.  
(A) Barplot depicts the high fraction of promoters bound by SMARCB1 in pediatric normal brain but 
repressed in ATRT (Figure 3B) that are bound by EZH2 (80%), which illustrates the role of EZH2 in gain 
of H3K27me3 at SMARCB1 binding sites in ATRT. See methods for the definition of EZH2-bound 
promoters.  
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(B) Snapshots display the PNB SMARCB1 and multilayer-overlay EZH2 ChIP-seq signal in ATRT 
subgroups, and the chromatin segmentations at EPHB1 (upper panel) and CNR1 (lower panel) in PNB 
(n=1) and ATRT subgroups (TYR, n=5, SHH, n=3, and MYC, n=3).  Boxplots next to the snapshots show 
the expression of the respective genes in ATRT subgroups and PNB.  
(C) Top three known enriched transcription factor motifs identified by Homer.  
(D) Boxplot showing the expression of REST in ATRT and PNB. * Wilcoxon test p value = 0.01. 
(E) The scatter plots shows the co-localization of REST and EZH2 at SMARCB1 bound repressed genes 
in ATRT. 
(F-G) Heatmaps displaying the scaled-read density for REST (F) and EZH2 (G) at regions surrounding ± 
5 kb TSS of the genes bound by SMARCB1 yet repressed in ATRT. At the top, density plot shows the 
average signal intensity displayed in the heatmap below. 
 
Figure 5. Delineation of a class of genes bound by EZH2 without H3K27me3 occupancy. 
(A) Scatter plot shows the comparison of the average EZH2 and H3K27me3 signal in ATRTs at 
promoter regions (±  1kb Tss) of protein-coding genes  (n=73104). Dashed red lines depict the cut-
offs used to define EZH2+ or H3K27me3+ promoters (See methods). Fractions of promoters with 
EZH2+/H3K27me3- and EZH2+/H3K27me3+  states are indicated as (1) and (2) on the plot, respectively.  
(B-C) Boxplots display the expression (B) and DNA methylation (C) levels of the genes associated with 
different H3K27me3/EZH2 promoter classes in ATRT as indicated in (A). *Wilcoxon test p value < 
2.2e-16.  
(D) Heatmaps depict the association of EZH2+/H3K27me3- promoters (n= 27483, EZH2+/H3K27me3- 
status in all ATRT subgroups) with active chromatin states and the preferential marking of 
EZH2+/H3K27me3+ promoters (n=7829, EZH2+/H3K27me3+ status in all ATRT subgroups) by repressed 
chromatin states, respectively at 200 bp windows surrounding ± 5kb TSS in ATRT. For visualization 
purposes, 1000 genes were randomly chosen from each category.  
See also Figure S5 and Table S3. 
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Figure 6. Residual SWI/SNF occupancy maintains gene and enhancer activity in ATRT.  
(A-B) Heatmaps displaying the scaled-read densities for EZH2 (blue), SUZ12 (brown), SMARCA4 (red) 
and H3K27me3 (dark gray) at regions surrounding ± 2 kb TSS of the genes highlight the co-
localization of EZH2, SUZ12 and SMARCA4 at EZH2+/H3K27me3- promoters (A) and the lack of 
SMARCA4 signal at EZH2+/H3K27me3+ promoters (B) in ATRT, respectively. At the top, density plots 
show the average signal intensities displayed in the heatmaps below. For visualization purposes, 
2000 randomly chosen promoters are shown either from EZH2+/H3K27me3- or EZH2+/H3K27me3+ 
classes.  
(C) Snapshot displaying the subgroup-multilayer EZH2, SUZ12 and SMARCA4 and H3K27me3 signals 
in ATRT-TYR (upper panel), ATRT-SHH (middle panel) and ATRT-MYC (lower panel) at CDK4 locus. 
(D) Heatmaps show the scaled average SMARCA4 signal in TYR, SHH and MYC subgroups at TYR-
specific enhancers (top panels), SHH-specific enhancers (middle panels) and MYC-specific enhancers 
(bottom panels), respectively. EMP refers to the enhancer coordinate midpoints.  
See also Figure S6 and Figure S7. 
 
Figure 7. SMARCA4 knock-down in ATRT cell lines.  
(A) Growth curves assay of SMARCA4 knockdown in BT12, BT16 and 293T cells. Each data point 
represents the average of two independent experiments. The data results of the growth curve were 
converted to a percentage, as the cells had different growth rate. The results were analyzed based on 
two  way variance analysis (ANOVA). The analysis was performed using GraphPad Prism 6.0 software 
(Version 7.00, GraphPad Software, San Diego, CA, USA, 2017). p ≤ 0.01 (*); p ≤ 0.001 (**), p ≤ 0.001 
(***) and p ≤ 0.0001 (****). 
(B) Cell cycle analysis after SMARCA4 knock-down in BT12 and BT16. * 2 way anova p value < 0.05. 
(C) qRT-PCR measuring expression of cell cycle genes (CDKN2A (p16), CDKN1A (p21), CCND3, CDK2 
and CDK6) in BT12 and BT16 cell lines at 5 days following SMARCA4 knock down calibrated to 
expression of the empty vector ; mean of triplicates, error bars represents standard deviation. 
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(D) Plots show the normalized H3K27me3 quantifications at CDKN2A, CDKN1A, CCND3, and CDK2, 
CDK6 promoters. Columns, mean of biological duplicates; bars, SD. *adjP < 0.05 , **adjP <0.005, 
***adjP <0.0005, and ****adjP  <0.0001,  relative to the Plko.1 control (two way Anova test). 
 
Figure 8. Model summarizing the Polycomb - SWI/SNF interplay in the regulation of enhancer and 
gene activity in ATRTs.  
 
STAR METHODS 
(see also Figure S8) 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
H3K27me3 Millipore 
Diagenode 
Cell Signaling 
Technologies 
Cat#07-449 
Cat#C15410195 
Cat#9733 
H3K4me1 ActiveMotif Cat#39298 
H3K4me3 ActiveMotif 
Diagenode 
Cat#39159 
Cat# C15410003-50 
H3K9me3 ActiveMotif Cat#39161 
H3K36me3 ActiveMotif Cat#61101 
EZH2 ActiveMotif 
Cell Signaling 
Technologies 
Cat#39901 
Cat#5246 
SMARCB1 Abcam Cat#12167 
SUZ12 ActiveMotif Cat#39357 
SMARCA4 Abcam 
Santacruz 
Cat#110641 
Cat# sc-17796 
REST Millipore Cat#17-641 
BAF47 BD Bioscience Cat#612110  
H3 Abcam 
Diagenode 
Cell Signaling 
Technologies 
Cat#1791 
Cat# C15210011 
Cat#9715 
B-actin Abcam Cat#49900 
Anti-Mouse IgG Abcam Cat#6728 
Anti-Rabbit IgG Abcam Cat#205718 
Bacterial and Virus Strains 
E.coli DH5α Invitrogen  Cat#18265017 
Chemicals, Peptides, and Recombinant Proteins 
Trypan blue Invitrogen Cat# T10282 
RNase Sigma-Aldrich Cat# R6148 
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Propidium iodide Sigma-Aldrich Cat# P4864 
SDS-PAGE loading buffer  ThermoScientific Cat# 11809340 
4-20% polyacrylamide Amersham ECL Gel GE Healthcare Cat#45-002-470 
SDS-PAGE Protein Ladder ThermoScientific Cat# 11842124 
PVDF Transfer Membrane ThermoScientific Cat# 88518 
Puromycin Gibco Cat# A1113803 
DMEM Sigma Cat# D5546 
L-glutamine Sigma Cat# G7513 
Pen-strep Sigma Cat# P4333 
Fetal bovine serum  Gibco Cat# 10082147 
Trizol ThermoFisher Scientific  Cat# 15596026 
Tet-Free FBS Clontech Cat# 631106 
 
Critical Commercial Assays 
CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7570 
Subcellular Protein Fractionation Kit Pierce Cat# 78840 
BCA Protein Assay Kit Pierce Cat# 23225 
SuperSignal West Pico Chemiluminescent Substrate Pierce Cat#34577 
DNA/RNA Miniprep Kit Zymo Cat#D7001 
RNA 6000 Nano Kit Agilent Cat# 5067-1512 
High-Capacity RNA-to-cDNA Kit Applied Biosystems Cat#4387406 
Platinum SYBR Green qPCR Supermix – UDG with 
ROX kit 
Invitrogen Cat# 11744500 
CalPhos™ Mammalian Transfection Kit Clontech Cat# 631312 
Senescence detection kit Sigma Aldrich Cat# CS0030-1KT 
DirectZol Mini Prep Plus Kit Zymo research Cat# R2070 
 
Deposited Data 
Raw data  This paper EGAS00001001297 
with dataset group 
number 
EGAD00001003408 
Experimental Models: Cell Lines   
Human: 293T ATCC Cat#CRL-3216 
Human: BT12   COG cells N/A 
Human: BT16  COG cells N/A 
Oligonucleotides 
GAPDH (RT-qPCR) F CAGGTCATCCATGACAACTTTG  Sigma Aldrich N/A 
GAPDH (RT-qPCR) R GTCCACCACCCTGTTGCTGTAG  Sigma Aldrich N/A 
CDKN2A (RT-qPCR) F CCCTCAGACATCCCCGATT  Sigma Aldrich N/A 
CDKN2A (RT-qPCR) R TCTAAGTTTCCCGAGGTTTCTCA  Sigma Aldrich N/A 
CDKN1A (RT-qPCR) F GGCAGACCAGCATGACAGATT  Sigma Aldrich  N/A 
CDKN1A (RT-qPCR) R GCGGATTAGGGCTTCCTCT  Sigma Aldrich 
 
N/A 
CCND1 (RT-qPCR) F GCCGTCCATGCGGAAGATC  Sigma Aldrich N/A 
CCND1 (RT-qPCR) R CCTCCTCCTCGCACTTCTGT  Sigma Aldrich N/A 
CCND3 (RT-qPCR) F CAGGCCTTGGTCAAAAAGCA  Sigma Aldrich N/A 
CCND3 (RT-qPCR) R GCGGGTACATGGCAAAGGTA  Sigma Aldrich N/A 
CDK6 (RT-qPCR) F CTTCGAGCACCCCAACGT  Sigma Aldrich N/A 
The chromatin landscape of atypical teratoid rhabdoid tumors 
 
32 
 
CDK6 (RT-qPCR) R GGTTTCTCTGTCTGTTCGTGACACT  Sigma Aldrich N/A 
CDK2 (RT-qPCR) F CCAGGAGTTACTTCTATGCCTGA Sigma Aldrich N/A 
CDK2 (RT-qPCR) R TTCATCCAGGGGAGGTACAAC Sigma Aldrich N/A 
CDK2 (ChIP-qPCR) F CGTTCATCTCTTTCCTCCTCT Sigma Aldrich N/A 
CDK2 (ChIP-qPCR) R GAGATTAGGAAAAGGGGTCTGA Sigma Aldrich N/A 
CDK6 (ChIP-qPCR) F GTGGTAGAAAGAATGTGTTT Sigma Aldrich N/A 
CDK6 (ChIP-qPCR) R GGACTCTAGTCACCCAGGAA Sigma Aldrich N/A 
CCND3 (ChIP-qPCR) F CGCATTCCTTAGAGCAAGCA Sigma Aldrich N/A 
CCND3 (ChIP-qPCR) R GGACTCTAGTCACCCAGGAA Sigma Aldrich N/A 
CDKN1A (ChIP-qPCR) F TATATCAGGGCCGCGCTG Sigma Aldrich N/A 
CDKN1A (ChIP-qPCR) R 
GGCTCCACAAGGAACTGACTTC 
Sigma Aldrich N/A 
CDKN2A (ChIP-qPCR) F CCCGTCCGTATTAAATAAACC Sigma Aldrich N/A 
CDKN2A (ChIP-qPCR) R GGGTGTTTGGTGTCATAGGG Sigma Aldrich N/A 
Recombinant DNA 
psPAx2 Addgene Cat# 12260 
pCDH-CMV-MCS-EF1-Puro System BioScience Cat# CD511B-1 
pMD2.G Addgene Cat# 12259 
Mission shRNA BRG1 Sigma Aldrich N/A  
pLKO.1-puro Sigma Aldrich Cat# SHC001 
Software and Algorithms 
FlowJo Stadnisky and Quinn. 2014 
 
https://www.flowjo.
com/ 
 
quasR Gaidatzis et al., 2015 https://bioconducto
r.org/packages/relea
se/bioc/html/QuasR.
html 
chromHMM Ernst and Kellis, 2012 http://compbio.mit.
edu/ChromHMM/ 
Bedtools Quinlan and Hall, 2010 http://bedtools.read
thedocs.io/en/latest
/ 
DeepTools Ramirez et al., 2014 https://deeptools.re
adthedocs.io/en/dev
elop/ 
MACS Zhang et al., 2008 http://liulab.dfci.har
vard.edu/MACS/ 
HOMER Heinz et al., 2010 http://homer.ucsd.e
du/homer/ 
Mclust N/A http://www.stat.wa
shington.edu/mclust 
R functions for analysis of next generation 
sequencing data 
Hisano et al., 2013 https://www.nature
.com/articles/nprot.
2013.145#suppleme
ntary-information 
ClueGO Bindea et al., 2009 http://apps.cytoscap
e.org/apps/cluego 
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CONTACT FOR REAGENT AND RESOURCE SHARING  
Further information and requests for resources should be directed to and will be fulfilled by the Lead 
Contact, Marcel Kool (m.kool@kitz-heidelberg.de).  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  
This study involves no new patient sample collection and informed consent exists for all patients 
contributing to the study. Patient samples, FF or formalin-fixed paraffin-embedded (FFPE) tumor 
sam- ples, and peripheral blood samples, were obtained from the EU-RHAB registry and the following 
single institutions: University Hospital Heidelberg, NN Burdenko Neurosurgical Institute, University of 
Muenster, McGill University, University of Barcelona, University of Prague, St. Judes Children’s 
Research Hospital, University of Bonn, University of Zuerich. All tumors were banked at the time of 
primary diagnosis between 2009 and 2015 in accordance with research ethics board approval from 
the respective institutes. Informed con- sent was obtained from all subjects included in the study.  
All samples were histologically verified ATRTs (as diagnosed by local pathologists using INI1 and 
SMARCA4 immunohistochemistry). DNA and RNA were isolated from the FF tumor samples, and only 
DNA was isolated from the FFPE tumor and blood samples using standard procedures. In a subset of 
tumor samples, the type of SMARCB1 mutation was characterized using MLPA, Sanger sequencing, or 
FISH as described above (Jackson et al., 2009). Molecular subgrouping was performed using either 
the 450k methylation or Affymetrix gene expression data (for subgroup information see Table S1).  
 
METHOD DETAILS 
ChIP-sequencing  
ChIP experiments and library preparation for H3K27me3, H3K4me1, H3K4me3, H3K9me3, 
H3K36me3, EZH2, SMARCB1, SUZ12, SMARCA4 and REST ChIP was performed at ActiveMotif 
(Carlsbad, CA) using antibodies against H3K27me3 (#07-449, Millipore), H3K4me1 (AM#39298, 
ActiveMotif), H3K4me3 (AM#39159, ActiveMotif), H3K9me3 (AM#39161,ActiveMotif) and 
H3K36me3 (AM#61101, ActiveMotif), EZH2 (AM#39901, ActiveMotif), SMARCB1 (ab12167, Abcam), 
SUZ12 (AM#39357, ActiveMotif), SMARCA4 (ab110641, Abcam) and REST (ab17-641, Millipore). 
Resulting libraries were sequenced on the Illumina HiSeq 2000 platform (single-end, read length: 50 
bp) according to the manufacturer’s instructions. Alignment, and downstream processing of ChIP-seq 
data was performed as described (Johann et al., 2016). Full list of the ChIP-seq libraries generated 
can be found in Table S1. H3K27ac ChIP-seq data was already available from (Johann et al., 2016). 
Example ChIP-qPCR data for the six histone modifications and number of aligned reads obtained for 
the respective histone modification ChIP-seqs are presented in Figure S8.  
ChIP-qPCR 
Cells were detached using 1% trypsin and washed twice with PBS. Cell were fixed with formaldehyde 
(1% final concentration; 28906, Pierce) for 8 m at RT, followed by 5 min incubation at RT with Glycine 
(50046, 125 mM final concentration).  Cells were washed twice with cold PBS and lysed by douncing 
with 20 gauge needle x 20 times in cold Farnham buffer (47 mM, PIPES- P8203 Sigma, 3 M KCl- P9333 
Sigma, 5% NP-40- I8896 Sigma; Proteinase inhibitors- 37491 Active motif); nuclei were resuspended 
in RIPA buffer (5% NP40, 5% Na deoxycholate- D6750 Sigma, 10% SDS, Proteinase inhibitors) and 
sonicated (Bioruptor; Diagenode) at high setting 30 seconds ON, 30 seconds OFF. 
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Immunoprecipitation was conducted with antibody specific to H3K27me3 (c15410069 Diagenode), 
H3 (ab12079 Abcam), and normal Rabbit IgG (ab171870, Abcam) coupled with M-280 Sheep Anti-
Rabbit (11204D, Thermofisher). Samples were incubated with to the beads slurry for 2 h, after the 
antibodies were coupled with the beads for 2h at 4C and washed with PBS/BSA (1xPBS, 5mg/ml BSA-
15260037 Thermofisher). The beads were washed LiCl Wash Buffer at RT (100 mM Tris pH 7.5- 
10812846001 Roche / 500 mM LiCl / 1% NP-40 / 1% sodium deoxycholate) and TE (10 mM Tris-HCl 
pH 7.5 / 0.1 mM EDTA-EDS Sigma) before being resuspeded in Elution Buffer (1% SDS- L6026 Sigma / 
0.1 M NaHCO3- S5761 Sigma). 
 
DNA were reverse cross-linked by incubation at 65 °C overnight, purified using ChIP DNA Clean & 
Concentrator Kit (D5205, Zymo research) and a fraction was used as template in real-time PCR 
reactions. DNA present in each immunoprecipitation was quantified by realtime qRT-PCR using gene-
specific primers on ViA7 (Applied Biosystems), using SYBR™ Green as previously described. All 
expression values were normalized against input DNA and IgG or H3.  
 
ModSpec Analysis of Histone Marks 
Histones were acid extracted, derivatized via propionylation, digested with trypsin, newly formed N-
termini were propionylated as previously described (Garcia et al., 2007), and then measured 3 
seperate times using the Thermo Scientific TSQ Quantum Ultra mass spectrometer coupled with an 
UltiMate 3000 Dionex nano-liquid chromatography system. The data was quantified using Skyline 
(MacLean et al., 2010), and represents the percent of each modification within the total pool of that 
tryptic peptide.  
 
Cell line cultures  
Cells were seeded at an appropriate density in T 175 cm2 flasks and incubated at 37°C in the 
presence of 5 % carbon dioxide. Cells were passaged upon growth to 80-90 % confluence. Cells were 
treated with trypsin, and then centrifuged to generate a cell pellet. Pellets were re-suspended in an 
appropriate volume of media before being counted either manually through the use of a 
haemocytometer or electronically via the Countess II FL Automated Cell Counter (Invitrogen). The 
viability was measured by staining an aliquot of the cells with Trypan blue (Invitrogen).  
 
Proliferation assay  
To assess the proliferative capability, CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was 
used. Briefly every 24 hours 25 μl of solution was added directly to the media. The fluorescence was 
measured using FLUOstar Omega (BMG Labtech) plate reader. All measurements were taken in 
quadruplicate/ quintuplicate.  
 
Protein extraction and quantification  
Proteins from cell lines were extracted from 1x106 cells, using NE-PER or Subcellular Protein 
Fractionation Kit for Cultured Cells (PIERCE). Proteins from patients were extracted using 30 μg of 
frozen tissue using Subcellular Protein Fractionation Kit for tissue with small modification; briefly 
tissue was washed twice with cold PBS and disrupted in CEB plus protein inhibitors using TissueLyser 
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II (Qiagen) (3 min/30 oscillation per minutes), the lysated tissue was filtered using 70 μm cell filter 
(BD) and spun down 300xg for 1 minute.  
Proteins extracted were quantified using the BCATM Protein Assay Kit (Pierce) according to the 
manufacturer’s instructions. The samples were incubated at 60°C for 30 minutes, the absorbance of 
the protein solutions were measured at 562 nm using FLUOstar Omega (BMG Labtech) plate reader.  
 
Protein electrophoresis and blotting  
Loading buffer (Lane Marker Reducing Sample Buffer Thermo-Scientific) was added to 5 μg or 1 μg of 
nuclear or chromatin protein respectively and the sample denatured at 95° C for 5 min, spun briefly 
and kept on ice. The samples and a molecular weight marker (Spectra Multicolor Broad Range 
Protein Ladder, Invitrogen) were loaded in a 4-20 % polyacrylamide Amersham ECL Gel (GE 
Healthcare, UK). The run was performed at a constant 160 mV in Tris – Glycine Running Buffer. The 
electrophoresed proteins were transferred to a nitrocellulose membrane (Pierce) in a Tris-Glycine- 
Ethanol Transfer Buffer, by application of an electrical field of 100 mV for 45 min. Then they were 
incubated in blocking solution.  
The membrane was incubated in a solution composed of primary antibodies in T-TBS (BAF47 1:1000, 
612110 BD Biosciences; SMARCA4 1:1000, sc-10760 SantaCruz , H3K27me3 1:20000, C15410196 
Diagenode; H3K27ac 1:20000, C15410196 Diagenode; H3 1:20000, ab1791 Abcam; B- actin:20000, 
ab49900 Abcam; Anti-Mouse IgG 1:10000, ab6728 Abcam; Anti-Rabbit IgG 1:10000, ab205718 
Abcam; ) for 1 hour at room temperature. It was washed three times in a solution of T-TBS then 
incubated in a diluted specific secondary antibody (1:10000) for 1 hour at room temperature and 
washed in T-TBS as before. The blot was developed using SuperSignal West Pico Chemiluminescent 
Substrate (Pierce) and imaged using ChemiDoc XRS+ (Biorad).  
  
DNA/RNA extraction, purification,  RNA quantification and quality assessment  
RNA was extracted from pellets of 1x106 cells using the ZymoBIOMICS DNA/RNA Miniprep Kit (Zymo). 
RNA samples were stored at -80 °C. RNA quality and quantity was assessed by Bioanalyzer (Agilent 
Technologies), using Agilent RNA 6000 Nano Kit respectively, following the manufactures procedure.  
 
Oligonucleotides  
All oligonucleotides were synthesized by Sigma Aldrich and re-suspended in nuclease free H2O 
(Invitrogen) to a concentration of 100 μmol/μl. Primers for q-PCR were designed using Primer3Plus 
software (version 4.0.0 and previously; http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi/). The transcript sequences of genes were extrapolated from 
Ensembl (http://www.ensembl.org/index.html). The primers were checked for non-specific product 
using UCSC In-Silico PCR software (https://genome.ucsc.edu/).  
 
RT-qPCR  
A total of 1000 ng of RNA was converted into cDNA using High-Capacity RNA-to-cDNA Kit (Applied 
Biosystems) in accordance with the manufacturer’s instructions.  
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The cDNA was amplified using the Platinum SYBR Green qPCR Supermix – UDG with ROX kit 
(Invitrogen, USA) using ViiA7 machine (Applied Biosystems, UK). The master mix provided is 
composed of AmpliTaq® DNA Polymerase and SYBR® Green cyanine dye, which as a result of binding 
to DNA absorbs blue light (λmax = 497 nm) and emits green light (λmax = 520 nm). General reaction 
conditions are shown below.  
 
We quantifed the gene expression data using the ΔΔCT method. The relative quantification measures 
the relative change in mRNA expression levels of a gene by comparing to the levels of another RNA. 
This method does not require a calibration curve and the gene expression is compared against a 
reference gene. In this study we chose as reference gene GAPDH, an endogenously expressed gene.  
The gene expression has been calculated following specifically ΔΔCT which assumes that each PCR 
cycle will doubles the amount of amplicons in the reaction (amplification efficiency = 100%) (Livak 
and Schmittgen, 2001). The fold change expression values have been calculated using this formula: 
Fold change expression =2-ΔΔCt where ∆∆Ct = [∆Ct sample1 – ∆Ct sample2] and ∆Ct = [Ct sample – Ct 
endogenous control]. 
 
Lentiviral Production and Infection  
For Lentiviral particle production, 3.5x106 HEK293T cells were co-transfected with 7.5 μg of 
expression vector and the packaging vectors 6 μg of psPAx2 and 1.8 μg pVSVg using Calcium 
Phosphate Transfection (CalPhos Transfection Kits, Clontech). Between twelve hours and fifteen 
hours after transfection, fresh media was added. Forty-eight hours after transfection, supernatant  
was collected and concentrated by ultrafiltration in Centricon Plus 100 (Millipore). Particles were 
aliquoted and stored at -80°C.  
 
Stable lentiviral infection of rhabdoid cells  
Lentiviral infection of rhabdoid cells was carried out aiming to transduce about 60%-80% of the total 
amount of cells in each experiment. Briefly, Viral particles (Multiplicity of infection of 10 and 5; 
SMARCB1+ and SMARCA4 respectively) were directly added to the media and the cells were 
incubated for 24 hours at 37°C and 5% CO2. To select for infected cells, Puromycin (Invitrogen) was 
added to the media to the final concentration of 1 μg/mL. The selection was prolonged up to 5 days 
(SMARCA4 k/d) or 7 days (SMARCB1 stable infection) post-infection, when cells were harvested.  
 
Plasmids  
The self-inactivating, CMV-derived, lentiviral vector pCDH-CMV-MCS-EF1-Puro was purchased from 
System BioScience. PCDH-CMV-MCS-EF1-Puro contains Ampicillin resistant gene for selection of the 
plasmid in E.coli and Puromycin-resistant marker for selection of the transfected/transduced cells. 
pBABE BRG1 dominant negative and shRNA pBABE BRG1 (K->R) were purchased from Addgene 
(plasmid 1960). Propagation of all the vectors (excluded pSIN-SIEW) was conducted in the E. coli 
strain DH5α.  
In order to transfect the human cell lines through the lentivirus technology, BRG1 sequence has been 
cloned in the suitable pCDH-CMV-MCS-EF1-Puro expression vector. Lentiviral shRNA clones in the 
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pLKO.1-puro vector were obtained from Sigma-Aldrich TRCN0000015551 
(CCGGCCGAGGTCTGATAGTGAAGAACTCGAGTTCTTCACTATCAGACCTCGGTTTTT) TRCN0000015552 
(CCGGCGGCAGACACTGTGATCATTTCTCGAGAAATGATCACAGTGTCTGCCGTTTTT); pLKO.1-puro empty 
vector (Sigma-Aldrich) was used as control.  
 
Cell cycle analysis  
Cell cycle stages were determined by measuring the cellular DNA content using flow cytometry. Cells 
were harvested, washed twice with PBS and fixed with 70% cold ethanol overnight at 4 °C. For cell 
cycle analysis, the cells were washed twice with cold PBS and centrifuged at 800 rpm for 5 minutes. 
The cells then were incubated with 100 μg/ml ribonuclease A, RNase (Sigma Aldrich) for 5 minutes 
followed by 30 minutes staining with 50 μg/ml propidium iodide, PI (Sigma Aldrich). Samples were 
analysed using a FACSCanto (BD Biosciences) and FlowJo software.  
 
Cell senescence analysis  
To determine senescence following SMARCA4 knockdown and SMARCB1 reexpression, MRT cells 
were seeded at a density of 1 x 105 in 6-well plate (Corning) and after 5 days or 7 days post-infection 
respectively, β-galactosidase was measured using senescence detection kit (Sigma Aldrich) according 
to manufacturer's protocols.  
 
EZH2 knock-down and RNA-seq 
For inducible expression of shRNAs, the pINDUCER10 vector (Meerbrey et al., 2011) was obtained 
from Addgene and linearized with XhoI/EcoRI double digestion. The sequences for targeting EZH2 
were obtained from the RNAi consortium (EZH2-2: TRCN0000286290, EZH2-3: TRCN0000293738) and 
have been previously validated in (Kim et al., 2015), and the sequence for the control (non-targeting) 
shRNA was obtained from (Sarbassov et al., 2005). The short-hairpin sequences were modified to 
generate a mir30-based hairpin using the shRNA retriever tool 
(http://katahdin.mssm.edu/siRNA/RNAi.cgi?type=shRNA). Oligos were obtained from IDT, annealed 
according to manufacturer’s instructions and ligated into pINDUCER10.  
BT16 cells were grown, selected and maintained at all times in McCoy’s 5A medium supplemented 
with 10% Tet-free FBS (Clontech, cat # 631106), 1% Glutamax. 2X105 BT16 cells stably expressing 
either shCTRL or shEZH2-3 were seeded in 6-well plates in triplicates. The next day (d0), fresh 
medium plus 5 ug/mL doxycycline (Clontech, Cat # 631311 ) was added and after 72 h, RNA was 
extracted using Trizol and the DirectZol Mini Prep Plu Kit (Zymo research, cat # R2070).  
RNA was quantified using the Quant-iT RiboGreen assay (Life Technologies) and quality checked by 
2100 Bioanalyzer RNA 6000 Nano assay (Agilent) or LabChip RNA Pico Sensitivity assay (PerkinElmer) 
prior to library generation.  Libraries were prepared from total RNA with the TruSeq Stranded mRNA 
Library Prep Kit according to the manufacturer’s instructions (Illumina.) libraries were analyzed for 
insert size distribution on a 2100 BioAnalyzer High Sensitivity kit (Agilent Technologies) or Caliper 
LabChip GX DNA High Sensitivity Reagent Kit (PerkinElmer.) Libraries were quantified using the 
Quant-iT PicoGreen ds DNA assay (Life Technologies) or low pass sequencing with a MiSeq nano kit 
(Illumina.) One hundred cycle paired end sequencing was performed on a NovaSeq 6000 (Illumina.) 
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RNAseq reads were mapped to human GRCh37-lite reference genome by STAR (Dobin et al., 2013). 
Gene level counts were quantified by HT-seq (Anders et al., 2015) against GENCODE annotation. 
Read counts were further normalized using TMM(trimmed mean of M values) (Robinson and 
Oshlack, 2010) methods from R package “EdgeR”.  Differential gene expression analysis was 
performed by R package “limma” (voom function) (Law et al., 2014). The gene were considered 
differentially expressed if adjusted p value is lower than 0.05 and the fold change is higher than 2. 
The gene ontology and KEGG pathway enrichment analyses were performed by R function goana and 
kegga from limma package. 
 
Genomic coordinates and gene annotation  
All coordinates used in this study are based on human reference genome assembly hg19, GRCh37 
(http://www.ncbi.nlm.nih.gov/assembly/2758/). Gene annotations are based on gencode annotation 
release 19 (http://www.gencodegenes.org/releases/19.html).  
 
Quantification of gene expression generated by RNA-seq 
Gene expression values in RPKM either for ATRT (Johann et al., 2016) or pediatric normal brain 
(Roadmap Epigenomics et al., 2015) were quantified using “qCount” function of Bioconductor 
package quasR (Gaidatzis et al., 2015). Pediatric normal brain RNA-seq data for the two samples 
HuFNSC01 and HuFNSC02 was obtained from http://www.genboree.org/EdaccData/Current- 
Release/sample-experiment/Fetal_Brain/mRNA-Seq/.  
   
Chromatin segmentation  
18-state Roadmap chromatin segmentation model (Roadmap Epigenomics et al., 2015), which was 
downloaded from 
http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/core_K2 
7ac/jointModel/final/ (file named as model_18_core_K27ac.txt was applied on ATRT histone 
modification ChIP-seq data. The data in bed format (generated using bamToBed function of bedtools 
(Quinlan and Hall, 2010)) was binarized and subsequently segmented using “BinarizeBed” and 
“MakeSegmentation” commands of the chromHMM tool (Ernst and Kellis, 2012). Binarization was 
done using default values. Genomic DNA controls were utilized as background in the identification of 
binarization thresholds. In the segmentation step, the downloaded Roadmap model 
(model_18_core_K27ac.txt) was used. This resulted in the chromatin segmentation of 11 ATRTs. 
Subsequently, “MakeBrowserFiles” command from the chromHMM tool (Ernst and Kellis, 2012) was 
used to generate segmentation files suitable for UCSC genome browser (Kent et al., 2002) 
visualization.  
 
Multi-track representation of the data  
For each histone ChIP-seq bam file, bigWig files were generated using bamCoverage function of 
deepTools (Ramirez et al., 2014) with rpkm as the normalization option. Track hubs were constituted 
for each ATRT separately and were visualized in UCSC genome browser (Kent et al., 2002) using a 
smoothing window of three pixels.  
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Comparison of chromatin state distributions  
Chromatin segmentations for all Roadmap tissues and cell lines where 18-state chromatin 
segmentation was available were downloaded from 
http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/core_K2 
7ac/jointModel/final/STATEBYLINE/. Chromatin segmentations for MB (n=23) and GBM (n=3), and 
pediatric normal brain (n=1) were done using the 18-state chromatin segmentation manner similar to 
ATRT. The coverage of each chromatin state in the genome was calculated in ATRT, MB, GBM, 
pediatric normal brain, adult brain (Roadmap) and ESC (Roadmap), and the resulting distributions 
were represented as boxplots (Figure 1B-1G, Figure S1A). In Figure 1B-1G, after performing ANOVA, 
pairwise t-test comparisons were performed and adjusted p values were obtained using Benjamini- 
Hochberg procedure.  
 
DNA methylation analysis  
Genomic regions with ReprPC state in PNB were analyzed for the corresponding chromatin states in 
ATRT subgroups (Figure S2A). To call a 200 bp window to be in a certain chromatin state within an 
ATRT subgroup, it was required that at least 50% of the samples from the respective subgroup should 
be in the state under question. Subsequently, the genomic regions with ReprPC state in pediatric 
normal brain were divided into two groups as “the regions with ReprPC state only in pediatric normal 
brain” and “the regions with ReprPC state both in ATRT subgroup and pediatric normal brain”. For 
the resulting genomic regions, DNA methylation values (Figure S2C) were calculated for each ATRT 
subgroup.  
 
Regions losing and gaining H3K27ac/H3K27me3  
Genome was tiled into 2kb windows and H3K27ac and H3K27me3 signals were quantified in BT16 
and BT12 ATRT cell lines before and after SMARCB1 re-expression. Genomic regions which were 
found to have log2 fold change of 0.5 and -0.5 after SMARCB1 re-expression were referred as the 
genomic regions gaining and losing the histone modifications, respectively (Figure 2B-2C, Figure S3G- 
S3H).  
 
Representation of the genomic regions  
Genome was classified into regions as exon, intron, intergenic and promoter (region surrounding ± 1 
kb transcriptional start sites) with the hierarchy: promoter > exon > intron > intergenic. 
Subsequently, each region was intersected with the genomic regions gaining or losing H3K27ac in 
BT16 and BT12 cell lines (Figure 2D-2E).  
 
Peak finding  
Peak finding for SMARCB1 and SMARCA4 was performed using MACS (Zhang et al., 2008) with 
default parameters.  
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SMARCB1 binding at different chromatin states  
For each of 18 chromatin states, the number of 200 bp bins which are in the respective chromatin 
state and falling into SMARCB1 peaks were counted in all ATRTs and pediatric normal brain. To 
evaluate the enrichment of chromatin states at SMARB1 bound regions, chromatin state frequencies 
at SMARCB1 bound regions were compared to the ones observed at random genomic regions. 
Random genomic regions with the same size, number and genomic distribution as SMARCB1 peaks 
(same exonic, intronic, intergenic, promoter coverage) were created using shuffle command from 
bedtools (Quinlan and Hall, 2010). Subsequently, for the resulting random genomic regions, the 
number of 200 bp bins in each chromatin state was calculated in ATRTs and PNB similarly to the 
calculation performed for SMARCB1 peaks. The resulting values for each chromatin state (arising 
from the calculation on SMARCB1 peak regions and random regions) were used to build contingency 
tables, apply Fisher’s exact test and calculate the odd ratios. In Figure S4A, chromatin state frequency 
counts averaged per subgroup were used to compare the counts at SMARCB1 peaks and random 
regions and apply Fisher’s exact test. Figure 3A, chromatin state frequency counts averaged across all 
ATRTs were used to perform the Fisher’s exact test in comparison of SMARCB1 peak regions with 
random regions.  
 
Chromatin states of the promoters bound by SMARCB1  
First, the genomic regions overlapping SMARCB1 binding sites which are in one of TssA, TssFlnkU, 
EnhG2, EnhA1, and EnhA2 chromatin states in pediatric normal brain were identified. For each 
subgroup, resulting regions were overlapped with the genomic regions falling into ± 2 kb surrounding 
transcriptional start sites and in one of TssBiv, EnhBiv, ReprPC, ReprPCWk and Quies chromatin 
states in the respective subgroup (to call a genomic region to be in a certain chromatin state, it was 
required that at least 50% of the samples from the respective subgroup should have the state). 
Genes with ± 2 kb surrounding transcriptional start sites satisfying this criteria in all ATRT subgroups 
were defined as the class of promoters “SMARCB1 bound and active in pediatric normal brain, and 
switched to repressed chromatin states in ATRT”. Resulting set of genes/promoters were used in the 
comparison H3K27ac and H3K27me3 signal in ATRT vs pediatric normal brain (Figure 3B), pathway 
enrichment analysis (Figure 3C) and the comparison of the gene expression between ATRT and 
pediatric normal brain (Figure S4B).  
 
Transcription factor motif finding  
“findMotifs” command of the HOMER software (Heinz et al., 2010) were utilized to perform the motif 
finding. To find the motifs enriched in the promoter regions bound by SMARCB1 and switched to 
repressed chromatin states in ATRT, regions of the respective promoter overlapping SMARCB1 peaks 
were used (Figure 4C).  
 
Promoters according to EZH2 and H3K27me3 status 
Initially, EZH2 and H3K27me3 signal intensities at promoter regions (± 1kb surrounding TSS) were 
calculated in rpkm using the functions described in (Hisano et al., 2013). For both EZH2 and 
H3K27me3, a single intensity value per promoter was obtained by taking the average over all ATRTs. 
Resulting values were modelled by fitting two normal distributions to the data using the R package 
‘mclust’ (http://www.stat.washington.edu/mclust). Using a p value cut-off of 0.0001, thresholds for 
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being H3K27me3-positive and EZH2-positive were determined as 0.931 and 0.780, respectively 
(Figure S5A-S5B). Subsequently, these thresholds were used to determine EZH2+ and H3K27me3+ 
promoters in each subgroup simply by checking which promoters have a subgroup average signal 
value greater or equal to the thresholds determined. Figure S5C-S5E show the comparison of EZH2 
and H3K27me3 in scatter plots for the three ATRT subgroups and thresholds were shown as dashed 
red lines. In Figure 4A, “Bound by EZH2” status refers to being EZH2 positive according to the cut-offs 
identified (Figure S5A-S5B) in all ATRT subgroups. Figure 5A displays EZH2+/H3K27me3- or 
EZH2+/H3K27me3+ promoters in all ATRTs irrespective of the subgroup. With similar usage of mclust 
package and using a p value cut-off of 0.001, H3K27me3-positive and EZH2-positive promoters were 
also defined for PNB (Figure S5G) and hESCs (Figure S5H).  
 
Chromatin states at different EZH2/H3K27me3 classes  
For each promoter class from EZH2+/H3K27me3- or EZH2+/H3K27me3+, the chromatin state of the 
each 200 bp genomic bin falling into the ± 5kb Tss region was determined in ATRTs. The assignment 
of the chromatin state was performed using the chromatin state with the maximum representation 
among all ATRTs. The results were displayed as heatmaps (Figure 5D).  
 
Plotting ChIP-seq signal around TSS  
To quantify ChIP-seq signal around transcriptional start sites of the genes “profilesForRegions” 
function was used as described (Hisano et al., 2013). To summarize, the read counts at each position 
within ± 2kb Tss regions (Figure 3B) were summed and averaged over 50 bp windows tiling the 
region. Resulting values were scaled to a range between 0-1 and plotted as heatmaps. In Figure 3B, 
to plot H3K27ac and H3K27me3 signals in ATRT, signal intensities were averaged across all ATRTs. 
Regarding the display of EZH2, SUZ12, SMARCA4 and H3K27me3 signals at different EZH2/H3K27me3 
promoter classes for ATRT-TYR, ATRT-SHH and ATRT-MYC (Figure S6), each ChIP-seq signal was 
averaged across the samples from the same subgroup. In order to create the heatmaps in Figure 6A-
6B, ChIP-seq signals from all ATRTs were averaged irrespective of the subgroup.  
 
Pathway enrichment analysis  
Functional annotation of the genes with promoter regions bound by SMARCB1 and switched to 
repressed chromatin states in ATRT (Figure 3C) was performed using ClueGO plugin for Cytoscape 
(Bindea et al., 2009) and using GO (Biological process, levels 8-15), KEGG, Reactome and Wiki 
pathways. Enriched pathways were determined using the following settings: go-term fusion option, p 
value threshold of 0.05 and other parameters as default. The output associated with only a single 
gene set was manually discarded.  
 
QUANTIFICATION AND STATISTICAL ANALYSES   
All meta analysis performed using bam files and statistical analyses were performed using R and 
bionconductor packages. Basic quantification of ChIP-seq data was performed using the functions 
“coverageForChr”, “countsForRegions” and “profilesForRegions” described in (Hisano et al., 2013).  
Quantification of published RNA-seq was done using “qCount” function of Bioconductor package 
quasR (Gaidatzis et al., 2015). ANOVA, and pairwise t-test comparisons to compare the chromatin 
The chromatin landscape of atypical teratoid rhabdoid tumors 
 
42 
 
state distributions across different tissue types (Figure 1); Fisher’s exact test to show differential 
representation of SMARCB1 binding sites at chromatin states (Figure 3) were performed in R.  
Analysis of differential representation of cell cycle phases, RT-qPCR and ChIP-qPCR  after SMARCA4 
knock-down in BT12 and BT16 were carried out using 2 way- ANOVA in (Figure 7).  
 
DATA AND SOFTWARE AVAILABILITY  
Short-read sequencing data have been deposited at the European Genome-Phenome Archive (EGA, 
http://www.ebi.ac.uk/ega/) hosted by the EBI, under accession number EGAS00001001297 with 
dataset group number EGAD00001003408. 
 
Table S1. Related to Figure 1. List of samples included in the study, including their subgroup 
affiliation, and generated ChIP-seq data availability. 
 
Table S2. Related to Figure 3. List of genes and their ± 2kb TSS regions, bound by SMARCB1 and 
active in PNB but associated with repressed chromatin states in ATRT (referring to Figure 3B). 
 
Table S3. Related to Figure 5. Promoters with upper 5th percentile EZH2 enrichments in ATRT, which 
are in EZH2+/H3K27me3- status. Table S3A shows the genes and promoter coordinates and TableS3B 
shows the pathways associated with the genes (Output of ClueGo pathway enrichment analysis). 
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Comprehensive	 analysis	 of	 chromatin	 states	in	 atypical	 teratoid/rhabdoid	 tumor	
identifies	diverging	roles	for	SWI/SNF	and	Polycomb	in	gene	regulation		
	
Serap	Erkek,	Pascal	D.	Johann,	Martina	A.	Finetti,	Yiannis	Drosos,	Hsien-Chao	Chou,	
Marc	Zapatka,	Dominik	Sturm,	David	T.W.	Jones,	Andrey	Korshunov,	Marina	
Rhyzova,	Stephan	Wolf,	Jan-Philipp	Mallm,	Katja	Beck,	Olaf	Witt,	Andreas	E.	Kulozik,	
Michael	C.	Frühwald,	Paul	A.	Northcott,	Jan	O.	Korbel,	Peter	Lichter,	Roland	Eils,	
Amar	Gajjar,	Charles	W.M.	Roberts,	Daniel	Williamson,	Martin	Hasselblatt,	Lukas	
Chavez,	Stefan	M.	Pfister,	Marcel	Kool		
TYR SHH MYC GBM MB ANB PNB ESC
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
TssA
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
0
0.
2
0.
4
0.
6
0.
8
TssFlnk
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
1
0.
2
0.
3
0.
4
0.
5
TssFlnkD
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
0
0.
2
0.
4
0.
6
0.
8
TssFlnkU
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
2
0.
4
0.
6
0.
8
TssBiv
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
1
2
3
4
5
6
Tx
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
5
1.
0
1.
5
EnhA1
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
5
1.
0
1.
5
2.
0
2.
5
EnhA2
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
5
1.
0
1.
5
EnhG1
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
0
0.
5
1.
0
1.
5
2.
0
EnhG2
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
EnhWk
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0.
0
0.
5
1.
0
1.
5
EnhBiv
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0
2
4
6
8
ReprPC
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
5
10
15
ReprPCWk
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
2
4
6
8
Het
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
0
1
2
3
ZNF_Rpts
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
TYR SHH MYC GBM MB ANB PNB ESC
50
60
70
80
Quies
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
A
B
ATRT PNB
0.
0
1.
0
2.
0
3.
0
H3
K2
7a
c (
log
2 
rp
km
)
C
ATRT PNB
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
TYR SHH MYC GBM MB ANB PNB ESC
8
10
12
14
16
TxWk
Co
ve
ra
ge
 in
 th
e 
ge
no
m
e 
(%
)
**
F
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
H3
K2
7a
c (
log
2 
rp
km
)
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
H3
K2
7m
e3
 (l
og
2 
rp
km
)
* *D E
ATRT ATRTMB MB
H3
K2
7m
e3
 (l
og
2 r
pk
m
)
ATRT
MB
H3K27ac
3
4
5
6
7
Pe
rc
en
t in
 a
ll h
ist
on
e 
m
od
ific
at
ion
s
H3K27me3
10
15
20
25
Pe
rc
en
t in
 a
ll h
ist
on
e 
m
od
ific
at
ion
s
The chromatin landscape of atypical teratoid rhabdoid tumors 
	
	
	
Figure	S1.	Related	to	Figure	1.	Distribution	of	the	chromatin	states	in	ATRT.		
(A)	 Boxplots	 show	 the	 coverage	 of	 each	 chromatin	 state	 across	 ATRT	 subgroups,	 GBM,	MB,	 ANB,	
PNB,	and	ESC.	
(B-C)	Boxplots	show	the	H3K27ac	(B)	and	H3K27me3	(C)	levels	at	10kb	windows	tiling	the	genome	in	
ATRT	 and	PNB.	 For	 the	 comparisons,	 10kb	windows	with	min	1	 rpkm	value	either	 in	ATRT	or	 PNB	
were	taken	into	account.	*Wilcoxon	test	p-value	<	2.2e-16.		
(D-E)	Boxplots	show	the	H3K27ac	(D)	and	H3K27me3	(E)	levels	at	10kb	windows	tiling	the	genome	in	
ATRT	and	MB.	For	the	comparisons,	10kb	windows	with	min	1	rpkm	value	either	in	ATRT	or	MB	were	
taken	into	account.	*Wilcoxon	test	p-value	<	2.2e-16.	
(F)	Mass	spectrometry	analysis	shows	the	H3K27ac	(left	panel)	and	H3K27me3	(right	panel)	levels	in	
ATRT	and	MB.		
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Figure	S2.	Related	to	Figure	1.	Polycomb	repressed	regions	in	PNB	largely	lack	H3K27me3	and	have	
increased	DNA	methylation	in	ATRT.		
(A)	Pie-charts	display	the	corresponding	chromatin	states	in	ATRT	subgroups	for	the	genomic	regions	
that	 are	 in	 ReprPC	 state	 in	 PNB.	 For	 visualization	 purposes,	 the	 representations	 of	 some	 of	 the	
chromatin	states	were	combined	as	indicated.		
(B)	Snapshots	show	the	H3K27me3	signal	at	selected	genomic	regions	 in	PNB	and	ATRT	subgroups.	
For	 ATRT	 subgroups,	 H3K27me3	 data	 is	 a	 multilayer	 overlay	 representing	 the	 samples	 from	 each	
subgroup.	
(C)	Boxplots	show	the	average	percentage	of	DNA	methylation	in	ATRT	subgroups	at	genomic	regions	
with	ReprPC	state	both	in	PNB	and	in	one	of	ATRT	subgroups	(dark	colors)	and	the	genomic	regions	
with	ReprPC	state	in	PNB	only	(light	colors).	*Wilcoxon	test	p-value	<	2.2e-16.		
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Figure	S3.	Related	to	Figure	2.	Phenotypic	and	H3K27me3	profiles	in	BT12	and	BT16	ATRT	cell	lines	
after	SMARCB1	re-expression.		
(A)	 Protein	 simple	WES	 system	 analysis	 confirming	 SMARCB1	 re-expression	 in	 BT12	 and	 BT16	 cell	
lines	at	7th	day	post	transfection;	293t	is	positive	control;	Β-actin	was	used	as	loading	control.	
(B)	Images	of	BT12	and	BT16	before	and	after	re-expression	of	SMARCB1.		
(C)	Growth	curve	(Luminescent	Assay)	over	7	days	showing	growth	arrest	in	BT12	and	BT16	following	
SMARCB1	re-expression;	mean	of	triplicates	error	bars	represents	standard	deviation.	
(D)	 SMARCB1	 stable	 re-expression	 causes	 suppression	 of	 colony	 formation	 BT12	 and	 BT16	 cells.	 7	
days	post	transfection,	colonies	were	stained	and	plates	were	photographed.	
(E)	 SMARCB1	 re-expression	 induces	 senescence.	 Evaluation	 of	 β-galactosidase	 activity	 in	 BT16	 and	
BT12	at	7th	post	infection.	Senescent	cells	are	stained	blue.		
(F)	Cell	cycle	analysis	using	propidium	iodide	(PI)	staining	and	flow	cytometry	at	3rd	and	5th	day	post	
infection.		Results	are	the	mean	±	SE	of	two	separate	experiments.	2	way	Anova	analysis	was	used	to	
test	the	significant	difference	between	each	group	and	the	empty	vector	control	 	are	shown	as	p	≤	
0.01	(*);	p	≤	0.001	(**),	p	≤	0.001	(***)	and	p	≤	0.0001	(****).	
(G-H)	MA	plots	 (left)	 show	 the	comparison	of	 the	average	H3K27me3	 levels	and	 log2	 fold	 changes	
after	SMARCB1	re-expression	for	BT12	(G)	and	BT16	(H)	in	2kb	windows	tiling	the	genome.		
(I)	Mass	spectrometry	analysis	showing	the	percent	change	in	H3K27ac	and	H3K27me3	levels		
after	re-expression	of	SMARCB1	in	BT12	and	BT16	cell	lines.	Error	bars	show	the	standard	deviation	
of	three	replicates.		
(J)	Snapshots	show	H3K27ac	profiles	before	and	after	re-expression	of	SMARCB1	 in	BT12	and	BT16	
cell	lines	at	UNC5C,	NDRG1	and	NEDD4L	loci.	Barplots	next	to	the	snapshots	show	the	average	log2	
fold	changes	of	expression	after	SMARCB1	re-expression	for	the	respective	genes	in	BT12	and	BT16.	
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Figure	S4.	Related	to	Figure	3.	Chromatin	states	at	SMARCB1	binding	sites	in	ATRT	subgroups.		
(A)	Heatmap	display	 the	observed	over	expected	chromatin	state	 frequencies	at	SMARCB1	binding	
sites	in	ATRT	subgroups	(See	STAR	Methods	for	details).		
(B)	Boxplot	shows	the	mean	expression	level	of	the	genes	from	Figure	3C	in	ATRT	and	PNB	confirming	
the	predicted	transcriptional	repression	in	ATRTs.	Wilcoxon	test	p-value=8.5e-48.		
(C)	 Contingency	 table	 built	 to	 test	 the	 enrichment	 of	 tumor	 suppressor	 genes	 (TSG)	 among	 genes	
bound	by	SMARCB1	in	PNB	and	switched	to	repressed	chromatin	states	in	ATRT.	Fisher’s	Exact	Test	
p-value=0.01272.		
(D)	Snapshot	(left	panel)	displays	the	PNB	SMARCB1	signal	and	the	chromatin	segmentations	in	PNB	
(n=1)	and	ATRT	subgroups	 (TYR,	n=5,	SHH,	n=3,	and	MYC,	n=3)	at	 the	WNK2	 locus.	The	expression	
level	of	WNK2	in	ATRT	subgroups	and	PNB	is	presented	as	boxplot	next	to	the	image.		
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Figure	S5.	Related	 to	Figure	5.	Definition	of	EZH2+	and	H3K27me3+	promoters	and	comparison	of	
H3K27me3	and	EZH2	in	ATRT	subgroups	and	in	other	entities.		
(A-B)	Density	plots	show	the	distribution	of	the	signal	(gray)	for	EZH2	(A)	and	H3K27me3	(B)	in	ATRT,	
and	resulting	separation	of	the	signal	as	foreground	(positive	for	H3K27me3	(A)	or	EZH2	(B))	(green)	
and	background	(negative	for	H3K27me3	(A)	or	EZH2	(B))	(blue)	at	a	p	value	threshold	of	0.0001	(red	
line).		
(C-E)	Scatter	plots	show	the	comparison	of	H3K27me3	and	EZH2	at	promoter	regions	of	the	genes	for	
ATRT-TYR	 (C),	 ATRT-SHH	 (D),	 ATRT-MYC	 (E)	 with	 red	 dashed	 lines	 depicting	 the	 cut-offs	 for	
H3K27me3	and	EZH2	as	identified	in	(A)	and	(B).		
(F)	Scatter	plot	showing	the	comparison	of	H3K27me3	and	EZH2	at	promoter	regions	of	the	genes	for	
BT16	(ATRT	cell	line).		
(G)	Scatter	plot	showing	the	comparison	of	H3K27me3	and	EZH2	at	promoter	regions	of	 the	genes	
for	PNB.	Red	dashed	 lines	depict	 the	cut-offs	 identified	 for	H3K27me3	 (0.771)	and	EZH2	 (1.177)	 in	
PNB	with	the	same	methodology	as	in	(A)	and	(B).		
(H)	 Scatter	 plot	 comparing	 the	 H3K27me3	 and	 EZH2	 illustrates	 the	 largely	 absence	 of	
EZH2+/H3K27me3-	 class	 of	 promoters	 in	 ESC.	 Red	 dashed	 lines	 depict	 the	 cut-offs	 identified	 for	
H3K27me3	(1.011)	and	EZH2	(2.015)	in	ESCs	with	the	same	methodology	as	in	(A)	and	(B).		
(I-K)	ChIP-qPCR	validations	for	H3K27me3	(I),	SUZ12	(J)	and	EZH2	(K)	at	selected	loci,	RBM14,	CDK4,	
SMARCE1,	HDAC2	(EZH2+	H3K27me3-)	and	NEUROD2	(EZH2+	H3K27me3+)	in	three	ATRTs.	ACTB	and	
Untr12	serve	as	negative	controls.			
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Figure	S6.	Related	to	Figure	6.	Residual	SWI/SNF	occupancy	at	EZH2+/H3K27me3-	promoters	across	
ATRT	subgroups.		
(A)	 Heatmaps	 (panels	 on	 the	 left)	 display	 scaled-read	 densities	 for	 EZH2	 (blue),	 SUZ12	 (brown),	
SMARCA4	(red)	and	H3K27me3	(dark	gray)	at	regions	surrounding	±	2	kb	transcriptional	start	sites	of	
the	genes	with	EZH2+/H3K27me3-	promoters	in	ATRT-TYR	(upper	panel)	and	with	EZH2+/H3K27me3+	
promoters	 in	 ATRT-TYR.	 For	 visualization	 purposes,	 2000	 randomly	 chosen	 promoters	 are	 shown	
either	from	EZH2+/H3K27me3-	or	EZH2+/H3K27me3+	classes.	Scatter	plot	(middle	panel)	showing	the	
comparison	between	average	EZH2	 in	ATRT-TYR	and	SMARCA4	 in	ATRT-TYR	at	promoter	regions	of	
the	genes.	Promoters	are	colored	according	to	their	EZH2/H3K27me3	status	in	ATRT-TYR.	Snapshots	
displaying	 the	multilayer	H3K27ac,	H3K27me3,	 EZH2,	 SUZ12	and	SMARCA4	 signals	 in	ATRT-TYR	 	 at	
BMP4	locus.		
(B-C)	 Same	 as	 in	 (A)	 for	 ATRT-SHH	 (B)	 and	 ATRT-MYC	 (C),	 respectively.	 Snapshots	 displaying	 the	
multilayer	H3K27ac,	H3K27me3,	EZH2,	SUZ12	and	SMARCA4	signals	in	ATRT-SHH	at	SOX11	 locus	(B)	
and	in	ATRT-MYC	at	MYC	(C)	locus,	respectively.	
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Figure	 S7.	 Related	 to	 Figure	 6.	 Overlap	 of	 SMARCA4	 and	 SMARCB1	 co-occupied	 regions	 with	
EZH2+/H3K27me3-	 and	 EZH2+/H3K27me3+	 promoters	 and	 residual	 SWI/SNF	 occupancy	 at	 ATRT	
subgroup	specific	enhancers.	
(A-B)	 Barplots	 show	 the	 percentage	 of	 EZH2+/H3K27me3-	 (A)	 or	 EZH2+/H3K27me3+	 (B)	 promoters	
overlapping	 both	 SMARCA4	 peaks	 in	 ATRT	 and	 SMARCB1	 peaks	 in	 PNB.	 In	 the	 analysis,	 only	 the	
SMARCA4	peaks	which	can	be	found	in	at	least	two	ATRTs	and	having	SMARCA4	enrichments	in	the	
upper	20th	percentile	were	used.			
(C)	 Heatmap	 displaying	 the	 scaled-read	 density	 for	 REST	 at	 regions	 surrounding	 ±	 5	 kb	 TSS	 of	 the	
genes	with	EZH2	+	/	H3K27me3	-	status.	At	the	top,	density	plot	shows	the	average	signal	 intensity	
displayed	in	the	heatmap	below.	
(D)	 Dose	 dependent	 reduction	 of	 EZH2	 levels	 upon	 increased	 concentration	 of	 doxycycline.	 BT16	
shCTRL	 or	 shEZH2-3	 cells	 were	 treated	 with	 either	 1	 or	 5	 ug/mL	 doxycycline	 and	 levels	 of	 EZH2,	
H3K27me3,	H3	and	ACTIN	(loading	controls)	were	determined	by	western	blot	after	72h.	
(E)	Volcano	plot	shows	the	log2	fold	change	in	gene	expression	after	EZH2	knock-down	in	BT16		
cells	 vs	 -log10	 (PValue).Genes	 which	 are	 significantly	 (log2FC	 >	 1	 and	 FDR	 <	 0.05)	 downregulated	
(n=695)	and	upregulated	(n=1151)	are	shown	with	a	red	color.		
(F)	Boxplots	show	the	average	H3K27me3	levels	 in	ATRT	for	upregulated	and	downregulated	genes	
according	to	their	EZH2/H3K37me3	status.	*	Wilcoxon-test	p-value	<	1.0	e-9.		
(G)	 Barplot	 shows	 the	 overlap	 of	 ATRT	 subgroup	 specific-enhancers	 (overlapping	 and	 non-
overlapping	with	super-enhancers)	with	SMARCA4	peaks.		
(H-J)	Scatter	plots	display	the	comparison	between	average	EZH2	and	SMARCA4	in	ATRT-TYR	at	TYR-
specific	 enhancers	 (n=2048)	 (H),	 in	ATRT-SHH	at	 SHH-specific	 enhancers	 (n=1126)	 (I),	 and	 in	ATRT-
MYC	at	MYC-specific	enhancers	(n=495)	(J).	Enhancers	contained	within	super-enhancers	are	shown	
in	orange/red	color.	
(K)	Scatter	plot	shows	the	comparison	of	EZH2	and	SMARCB1	at	all	promoters.	Pearson	correlation	
coefficient,	r=0.88.		
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(L)	 Heatmaps	 display	 scaled-read	 densities	 for	 EZH2	 (blue),	 SMARCB1	 (red)	 and	 H3K27me3	 (dark	
gray)	 at	 regions	 surrounding	 ±	 2	 kb	 transcriptional	 start	 sites	 of	 the	 genes	with	 EZH2+/H3K27me3-	
promoters	 in	 PNB.	 EZH2+/H3K27me3-	 promoters	 in	 PNB	 were	 defined	 (Figure	 S5G)	 similarly	 as	 in	
ATRT.	 For	 visualization	 purposes,	 2000	 randomly	 chosen	 promoters	 are	 shown	 from	
EZH2+/H3K27me3-	class.			
(M)	Protein	simple	WES	system	analysis	confirming	SMARCA4	knock	down	in	BT12	and	BT16	cell	lines	
over	time	(3	days	and	7	days	post	transfection);	Β-actin	was	used	as	loading	control.	
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Figure	S8.	Related	to	STAR	Methods.	Quality	metrics	for	ChIP-seq.		
(A)	ChIP-qPCR	data	for	one	selected	ATRT	for	the	histone	modifications,	H3K4me1	(Untr12:	negative	
control,	ACTB	ln3:	positive	control),	H3K4me3	(Untr12	and	Untr4:	Negative	controls,	ACTB	-145	and	
GAPDH	pro:	positive	controls),	H3K27me3	(ACTB	-145:	Negative	control,	MYT1	-1772,	PTGER3	+1149	
and	CCND2	+47:	positive	controls),	H3K27ac	(Untr12	and	SNGH8	+1137:	negative	controls	and	ACTB	-
145:	positive	control),	H3K9me3	(Untr12:	negative	control,	ZNF184	+20k	and	ZNF678	+90k:	positive	
controls)	and	H3K36me3	(Untr12:	negative	control,	ACTB	ln3:	positive	control).	Data		was	generated	
by	 from	 Active	 Motif.	 ‘Untr’	 specifies	 ‘untranslated	 region’,	 ‘pro’	 specifies	 ‘promoter’,	 ‘+’	 or	 ‘-‘	
specifies	the	distance	from	the	transcriptional	start	sites	of	the	genes.		
(B)	 Table	 shows	 the	 number	 of	 mapped	 reads	 for	 the	 six	 histone	 modfications	 in	 ATRT	 ChIP-seq	
cohort.	
(C)	Scatter	plot	shows	the	correlation	between	technical	replicates	of	H3K27me3	generated	from	
the	same	primary	ATRT	sample	at	2kb	windows	tiling	the	genome.	
	
